Edwards Lifesciences Stock: Analyst Estimates & Ratings
Shares of the Irvine, California-based company have underperformed the broader market over the past 52 weeks. EW stock has increased 17.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 18.7%. Moreover, shares of the company have risen 4.9% on a YTD basis, compared to SPX's 9.7% return.
More News from Barchart
Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing
BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here?
Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.
Looking closer, Edwards Lifesciences stock has outpaced the Health Care Select Sector SPDR Fund's (XLV) 12.1% decrease over the past 52 weeks.
Shares of Edwards Lifesciences rose 5.5% following its Q2 2025 results on Jul. 24, with adjusted EPS of $0.67 and sales of $1.5 billion, both exceeding estimates and showing strong year-over-year growth. Segment strength was led by TAVR sales of $1.1 billion, TMTT sales of $134.5 million, and Surgical Structural Heart sales of $267 million. The company also raised its 2025 sales growth guidance to $5.90 billion - $6.10 billion and projected adjusted EPS at the high end of $2.40 - $2.50.
For the fiscal year ending in December 2025, analysts expect EW's adjusted EPS to grow 2.9% year-over-year to $2.50. The company's earnings surprise history is promising. It topped or met the consensus estimates in the last four quarters.
Among the 30 analysts covering the stock, the consensus rating is a 'Moderate Buy.' That's based on 15 'Strong Buy' ratings, one 'Moderate Buy,' 13 'Holds,' and one 'Strong Sell.'
This configuration is more bullish than three months ago, with 12 'Strong Buy' ratings on the stock.
On Jul. 25, RBC Capital raised its price target on Edwards Lifesciences to $89 with an 'Outperform' rating.
As of writing, the stock is trading below the mean price target of $87.28. The Street-high price target of $101 implies a modest potential upside of 30% from the current price levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Should You Think About Buying LION E-Mobility AG (ETR:LMIA) Now?
LION E-Mobility AG (ETR:LMIA), is not the largest company out there, but it led the XTRA gainers with a relatively large price hike in the past couple of weeks. While good news for shareholders, the company has traded much higher in the past year. Less-covered, small caps tend to present more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could the stock still be trading at a low price relative to its actual value? Let's take a look at LION E-Mobility's outlook and value based on the most recent financial data to see if the opportunity still exists. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. What's The Opportunity In LION E-Mobility? Good news, investors! LION E-Mobility is still a bargain right now. According to our valuation, the intrinsic value for the stock is €2.18, but it is currently trading at €1.41 on the share market, meaning that there is still an opportunity to buy now. However, given that LION E-Mobility's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility. See our latest analysis for LION E-Mobility What kind of growth will LION E-Mobility generate? Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. LION E-Mobility's earnings over the next few years are expected to increase by 100%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. What This Means For You Are you a shareholder? Since LMIA is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation. Are you a potential investor? If you've been keeping an eye on LMIA for a while, now might be the time to enter the stock. Its prosperous future outlook isn't fully reflected in the current share price yet, which means it's not too late to buy LMIA. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed investment decision. If you want to dive deeper into LION E-Mobility, you'd also look into what risks it is currently facing. To that end, you should learn about the 4 warning signs we've spotted with LION E-Mobility (including 1 which is significant). If you are no longer interested in LION E-Mobility, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
23 minutes ago
- Yahoo
Is CRISPR Therapeutics' (CRSP) Rising Net Loss a Sign of Bold Investment or Growing Pressure?
CRISPR Therapeutics AG recently reported its second quarter 2025 earnings, posting revenue of US$892,000, up from US$517,000 a year ago, but recording a net loss of US$208.55 million, up from US$126.41 million in the same period last year. Despite modest revenue gains, the significantly wider loss per share suggests rising costs or investment pressures are impacting the company's financial trajectory. We'll explore how the widening net loss and higher reported expenses could reshape CRISPR Therapeutics' investment narrative going forward. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. What Is CRISPR Therapeutics' Investment Narrative? To be a shareholder in CRISPR Therapeutics, you need conviction in the promise of gene-editing breakthroughs and the company's ability to translate pipeline progress into eventual commercial returns. The latest earnings report, though, spotlights a widening net loss and sharply higher operating expenses. While ongoing clinical trials and recent index inclusions remain key near-term catalysts, the size of the reported quarterly loss raises questions around cash burn and the timeline to profitability. This new financial data could shift expectations for the pace of hiring, R&D investment, or the need for additional funding, potentially affecting sentiment around CRISPR's risk profile. On balance, the recent news does not appear to instantly derail the main product development catalysts investors were tracking, but it sharpens focus on the sustainability of current spending levels and paths to revenue growth in a high-cost environment. But with losses widening, funding needs are something every investor should watch closely. CRISPR Therapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be. Exploring Other Perspectives Eighteen members of the Simply Wall St Community offer fair value estimates for CRISPR Therapeutics, ranging from US$14.57 to US$150.97 per share. As these forecasts reveal, opinions differ widely on the company's trajectory, particularly given growing expenses flagged in the latest earnings. Exploring several alternative viewpoints can help you understand the breadth of market expectations. Explore 18 other fair value estimates on CRISPR Therapeutics - why the stock might be worth less than half the current price! Build Your Own CRISPR Therapeutics Narrative Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Our free CRISPR Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CRISPR Therapeutics' overall financial health at a glance. Ready For A Different Approach? Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped: Find companies with promising cash flow potential yet trading below their fair value. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CRSP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Can Hudson Pacific Properties' (HPP) Revised Outlook Reveal Deeper Shifts in Its Core Business Strategy?
Earlier this month, Hudson Pacific Properties reported second quarter and half-year results showing declines in sales and revenue alongside increased net losses, and provided updated earnings guidance for 2025 with GAAP non-cash revenue projected between US$5.5 million and US$10.5 million. The combination of disappointing financial performance and revised outlook reflects ongoing challenges facing the company's core office and studio segments in the current market. Let's assess how the weaker quarterly results and revised guidance could affect Hudson Pacific Properties' longer-term investment narrative. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. Hudson Pacific Properties Investment Narrative Recap To be a shareholder in Hudson Pacific Properties, you need to believe that its portfolio of office and studio assets can eventually overcome weak occupancy trends and sustain a turnaround, primarily through a recovery in West Coast tech and media leasing and studio show count. The latest quarterly results show further declines in revenue and deepening losses, putting near-term pressure on the company's largest catalyst: improved leasing velocity. However, the risk from elevated leverage and constrained cash flow remains front and center, as the results reflect limited margin for error in the current environment. The company's recent follow-on equity offering, raising US$599.28 million, stands out as a significant move closely tied to the need for financial flexibility highlighted in its Q2 report. While this strengthens immediate liquidity, it also points to increased dilution, which could temper any positive impact from operational improvements in the short term. But with leverage still high, investors should be monitoring how these capital moves play into... Read the full narrative on Hudson Pacific Properties (it's free!) Hudson Pacific Properties is projected to reach $910.8 million in revenue and $70.9 million in earnings by 2028. This outlook is based on an expected annual revenue growth rate of 4.7% and a $493.7 million increase in earnings from the current level of -$422.8 million. Uncover how Hudson Pacific Properties' forecasts yield a $3.24 fair value, a 20% upside to its current price. Exploring Other Perspectives Fair value estimates from the Simply Wall St Community range from US$3.24 to US$28.64, across 3 distinct perspectives. With recent losses and slower leasing activity, the risk of continued revenue shortfalls is something readers should keep on their radar as opinions differ widely on future potential. Explore 3 other fair value estimates on Hudson Pacific Properties - why the stock might be worth just $3.24! Build Your Own Hudson Pacific Properties Narrative Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd. A great starting point for your Hudson Pacific Properties research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision. Our free Hudson Pacific Properties research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hudson Pacific Properties' overall financial health at a glance. Ready For A Different Approach? Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped: Uncover the next big thing with financially sound penny stocks that balance risk and reward. This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality. Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include HPP. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
